A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2017-10-17
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of
TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.